BioStock: Cereno Scientific receives IND acceptance for phase II start

The FDA has accepted Cereno Scientific’s Investigational New Drug application for the company’s lead drug candidate CS1. This allows Cereno to start the planned phase II study in patients with pulmonary arterial hypertension at clinical sites in the US. BioStock was able to put together a panel discussion to learn more about the importance of this milestone. The panel includes Cereno’s CEO Sten R Sörensen as well as CMO Björn Dahlöf, and the Principal Investigator of the study Dr Raymond Benza.

Read the Q&A with Sten R Sörensen, Björn Dahlöf and Dr Raymond Benza at biostock.se:

https://www.biostock.se/en/2021/09/cereno-scientific-receives-ind-acceptance-for-phase-ii-start/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se